Introduction
Methods
Donors aged > 55 years or with ≥ 3 risk factors | Donors with rest wall motion abnormalities | Donors with hemodynamic instability/LV dysfunction | |
---|---|---|---|
N. initially recruited | 97 | 6 | 15 |
N. potentially eligible studied patients | 57 | 6 | 15 |
Intervention (stress) | DIP (dob) | DIP (dob) | HT |
Echo assessment following intervention | Minutes | Minutes | Hours |
WMSI rest | 1 | > 1 | 1/> 1 |
WMSI peak | 1 | 1 | |
LVEF% rest | 59 ± 10 | 53 ± 8 | 48 ± 14 |
LVEF% peak | 67 ± 9 | 58 ± 7 | 59 ± 3 |
Contractile reserve | + | + | + |
Viability | NA | + | + |
Stress dismissed | N = 15 | N = 3 | |
Eligible non-transplanted | N = 9 | - | N = 7 |
Eligible transplanted hearts | N = 32 | N = 3 | N = 8 |
Donor characteristics of transplanted hearts | |||
Age (years) | 55 ± 7 | 34 ± 13 | 50 ± 9 |
Male gender | 53 (58%) | 3 (50%) | 8 (53%) |
BSA (m2) | 1.81 ± 0.19 | 1.95 ± 0.14 | 1.90 ± 0.19 |
Cause of death
| |||
Anoxia | 1 | - | - |
Cerebrovascular accident | 22 | 1 | 7 |
Head trauma | 9 | 2 | 1 |
Troponin > 0.14 micrograms/L | 21 | 3 | 8 |
Ethical committee
Coronary angiography
Statistical analysis
Results
Donors aged > 55 years or with ≥ 3 risk factors | Donors with rest wall motion abnormalities | Donors with hemodynamic instability/LV dysfunction | |
---|---|---|---|
Eligible transplanted hearts | N = 32 | N = 3 | N = 8 |
Cold ischemia time (minutes) | 178 ± 26 | 161 ± 16 | 150 ± 19 |
Recipient characteristics
| |||
Age (years) | 56 ± 9 | 53 ± 4 | 56 ± 7 |
Male gender | 26 | 3 | 4 |
UNOS state
| |||
1A
| 2 | 3 | |
1B
| 7 | ||
2
| 23 | 3 | 5 |
Recipient disease
| |||
DCM | 9 | 3 | |
DC CHD | 12 | 1 | 3 |
DC Valvular | 2 | 1 | |
HCM | 4 | 1 | |
Restrictive CMP in amyloidosis | 3 | 1 | |
DC other | 2 | 1 | |
TX associated to heart TX | 2 (Liver N = 1, Kidney N = 1) | ||
Survivors N | 27 | 3 | 7 |
FOLLOW-UP, months | 44 ± 24 | 24 ± 7 | 31 ± 4 |
Death, N | 5 | - | 1 |
Deaths (cause, post TX months)
| |||
PGF | 2 (2 months) | ||
Sepsis | 1 (2 months) | 1 (18 months) | |
Cancer | 1 (16 months) | ||
Recurrent systemic myeloma | 1 (32 months) |